Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bakris

Showing results (661-670 of 738) with videos related to

Pageof 74
Sort By:
American Journal of Hypertension|January 3, 2009
G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactionsVibha Bhatnagar, Daniel T O'Connor, Victoria H Brophy, et al.
Journal of the American College of Cardiology|May 27, 2014
Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3George L Bakris, Raymond R Townsend, Minglei Liu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 2, 2021
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A <i>Post Hoc</i> Analysis of the SONAR Randomized TrialSimke W Waijer, Ron T Gansevoort, George L Bakris, et al.
International Journal of Cardiology|May 4, 2016
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approvalFaiez Zannad, Patrick Rossignol, Wendy Gattis Stough, et al.
Clinical Cardiology|May 11, 2012
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 TrialDavid E Kandzari, Deepak L Bhatt, Paul A Sobotka, et al.
Journal of the American College of Cardiology|April 4, 2015
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trialGeorge L Bakris, Raymond R Townsend, John M Flack, et al.
Clinical Kidney Journal|March 3, 2023
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney diseaseRajiv Agarwal, Bertram Pitt, Biff F Palmer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 11, 2024
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trialHiddo J L Heerspink, Rajiv Agarwal, George L Bakris, et al.
Journal of the American Society of Nephrology : JASN|June 24, 2003
The rationale and design of the AASK cohort studyLawrence J Appel, John Middleton, Edgar R Miller, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 13, 2023
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysisGerasimos Filippatos, Stefan D Anker, Phyllis August, et al.
Pageof 74

Showing results (661-670 of 738) with videos related to

Sort By:
Pageof 74
American Journal of Hypertension|January 3, 2009
G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactionsVibha Bhatnagar, Daniel T O'Connor, Victoria H Brophy, et al.
Journal of the American College of Cardiology|May 27, 2014
Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3George L Bakris, Raymond R Townsend, Minglei Liu, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 2, 2021
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A <i>Post Hoc</i> Analysis of the SONAR Randomized TrialSimke W Waijer, Ron T Gansevoort, George L Bakris, et al.
International Journal of Cardiology|May 4, 2016
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approvalFaiez Zannad, Patrick Rossignol, Wendy Gattis Stough, et al.
Clinical Cardiology|May 11, 2012
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 TrialDavid E Kandzari, Deepak L Bhatt, Paul A Sobotka, et al.
Journal of the American College of Cardiology|April 4, 2015
12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trialGeorge L Bakris, Raymond R Townsend, John M Flack, et al.
Clinical Kidney Journal|March 3, 2023
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney diseaseRajiv Agarwal, Bertram Pitt, Biff F Palmer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 11, 2024
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trialHiddo J L Heerspink, Rajiv Agarwal, George L Bakris, et al.
Journal of the American Society of Nephrology : JASN|June 24, 2003
The rationale and design of the AASK cohort studyLawrence J Appel, John Middleton, Edgar R Miller, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|January 13, 2023
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysisGerasimos Filippatos, Stefan D Anker, Phyllis August, et al.
Pageof 74